---
title: "Rexulti (brexpiprazole), all indications: Pharmacology questions"
description: "Pharmacology questions on Rexulti (brexpiprazole) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Rexulti work (mechanism of action)? Which receptors does Rexulti bind to? What is the half-life of Rexulti? When does Rexulti reach peak and steady-state levels? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/rexulti/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole), all indications: Pharmacology questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)

## Mechanism

<a id="rexulti-mechanism"></a>

### How does Rexulti work (mechanism of action)?

> “The mechanism of action of REXULTI in the adjunctive treatment of major depressive disorder, treatment of 
> agitation associated with dementia due to Alzheimer’s disease, or treatment of schizophrenia is unknown. 
> However, the efficacy of REXULTI may be mediated through a combination of partial agonist activity at 
> serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.”

Source: [REXULTI: Prescribing information, page 25, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=25)

> “The mechanism of action of REXULTI is unknown.”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Clinical Pharmacology, captured 2026-11-13](https://www.rexultihcp.com/mdd/clinical-pharmacology#:~:text=The%20mechanism%20of%20action%20of%20REXULTI%20is%20unknown.)

> “The pharmacology data of REXULTI do not provide further insights on the mechanism of action.”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Clinical Pharmacology, captured 2026-11-13](https://www.rexultihcp.com/mdd/clinical-pharmacology#:~:text=The%20pharmacology%20data%20of%20REXULTI,on%20the%20mechanism%20of%20action.)

<a id="rexulti-receptor-binding"></a>

### Which receptors does Rexulti bind to?

> “Brexpiprazole has affinity (expressed as Ki) for multiple monoaminergic receptors including serotonin 5-HT1A 
> (0.12 nM), 5-HT2A (0.47 nM), 5-HT2B (1.9 nM), 5-HT7 (3.7 nM), dopamine D2 (0.30 nM), D3 (1.1 nM), and 
> noradrenergic α1A (3.8 nM), α1B (0.17 nM), α1D (2.6 nM), and α2C (0.59 nM) receptors. Brexpiprazole acts as a 
> partial agonist at the 5-HT1A, D2, and D3 receptors and as an antagonist at 5-HT2A, 5-HT2B, 5-HT7, α1A, α1B, α1D, 
> and α2C receptors. Brexpiprazole also exhibits affinity for histamine H1 receptor (19 nM) and for muscarinic M1 
> receptor (67% inhibition at 10 µM).”

Source: [REXULTI: Prescribing information, page 25, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=25)

> “<sup>a</sup>The binding affinity of brexpiprazole was determined in vitro in cells overexpressing human receptors and is expressed as an nM concentration with lower values representing higher affinity. High binding affinity Ki <1 nM.<sup>7</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Clinical Pharmacology, captured 2026-11-13](https://www.rexultihcp.com/mdd/clinical-pharmacology#:~:text=binding%20affinity%20of%20brexpiprazole%20was,High%20binding%20affinity%20Ki%20%3C1)

## Pharmacokinetics

<a id="rexulti-half-life"></a>

### What is the half-life of Rexulti?

> “After multiple once-daily administrations of REXULTI, the terminal elimination half-lives of brexpiprazole and its 
> major metabolite, DM-3411, were 91 hours and 86 hours, respectively.”

Source: [REXULTI: Prescribing information, page 26, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=26)

<a id="rexulti-peak-steady-state"></a>

### When does Rexulti reach peak and steady-state levels?

> “After single-dose administration of REXULTI tablets, the peak plasma brexpiprazole concentrations occurred 
> within 4 hours after administration, and the absolute oral bioavailability was 95%. Brexpiprazole steady-state 
> concentrations were attained within 10 to 12 days of dosing.”

Source: [REXULTI: Prescribing information, page 26, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=26)

<a id="rexulti-protein-binding"></a>

### Is Rexulti highly protein bound?

> “The volume of distribution of brexpiprazole following intravenous administration is high (1.56 ± 0.42 L/kg), 
> indicating extravascular distribution. Brexpiprazole is highly protein bound in plasma (greater than 99%) to 
> serum albumin and α1-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment. 
> Based on results of in vitro studies, brexpiprazole protein binding is not affected by warfarin, diazepam, or 
> digitoxin.”

Source: [REXULTI: Prescribing information, page 26, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=26)

<a id="rexulti-metabolism"></a>

### How is Rexulti metabolized?

> “In vivo brexpiprazole is metabolized primarily by CYP3A4 and CYP2D6 enzymes. After single- and multiple-
> dose administrations, brexpiprazole and its major metabolite, DM-3411, were the predominant drug moieties in 
> the systemic circulation. At steady-state, DM-3411 represented 23% to 48% of brexpiprazole exposure (AUC) 
> in plasma. DM-3411 is considered not to contribute to the therapeutic effects of brexpiprazole.”

Source: [REXULTI: Prescribing information, page 26, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=26)

> “Based on in vitro data, brexpiprazole showed little to no inhibition of CYP450 isozymes.”

Source: [REXULTI: Prescribing information, page 26, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=26)

<a id="rexulti-excretion"></a>

### How is Rexulti eliminated from the body?

> “Following a single oral dose of [<sup>14</sup>C]-labeled brexpiprazole, approximately 25% and 46% of the administered 
> radioactivity was recovered in the urine and feces, respectively. Less than 1% of unchanged brexpiprazole was 
> excreted in the urine, and approximately 14% of the oral dose was recovered unchanged in the feces.”

Source: [REXULTI: Prescribing information, page 26, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=26)

## Components

<a id="rexulti-inactive-ingredients"></a>

### What are the inactive ingredients in Rexulti?

> “REXULTI tablets are for oral administration and are available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg 
> strengths. Inactive ingredients include lactose monohydrate, corn starch, microcrystalline cellulose, 
> hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, and talc. 
> Colorants include titanium dioxide, iron oxide, and ferrosoferric oxide.”

Source: [REXULTI: Prescribing information, page 25, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=25)

## Related pages
- [Medical information: Rexulti (brexpiprazole): All indications](https://www.evicenter.com/medical-information/rexulti)
- [Indication](https://www.evicenter.com/medical-information/rexulti/indication)
- [Safety](https://www.evicenter.com/medical-information/rexulti/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/rexulti/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti/access-and-coverage)
